Overview

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

Status:
Completed

Trial end date:
2006-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate whether there is a difference in proportion of patients with resolution of heartburn and other symptoms related to gastroesophageal reflux disease (GERD) after four weeks of treatment with esomeprazole (NEXIUM®) in those subjects with Erosive Esophagitis (EE) and those without EE.

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Esomeprazole